Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02310100 · ClinicalTrials.gov registry record · NA
TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study
A NA study of Paroxysmal Atrial Fibrillation, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 178
- Enrollment target
- 20
- Study locations
NCT02310100 is a NA study of Paroxysmal Atrial Fibrillation that has completed, run by Abbott Medical Devices. The registered enrollment target is 178 participants, below the 852-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT02310100, a NA study of Paroxysmal Atrial Fibrillation, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 178 participants
- Enrollment target
- 20
- Study locations
Study Summary
A prospective, multicenter, interventional study to collect confirmatory evidence on the safety and effectiveness of the TactiCath® percutaneous ablation catheter in the post approval setting for the treatment of symptomatic paroxysmal atrial fibrillation using contact force assisted irrigated radiofrequency ablation.
Conditions Studied
Interventions
- DEVICE TactiCath Quartz treatment
Study Locations (20)
California
- Glendale Memorial Hospital and Health Center - Glendale
- Regional Cardiology Associates - Sacramento
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Womens Hospital - Boston
Michigan
- Cardiology Consultants of East Michigan - Flint
- Providence Hospital - Southfield
New York
- Mount Sinai Hospital - New York
- Stony Brook University Medical Center - Stony Brook
Texas
- Texas Cardiac Arrhythmia - Austin
- The Methodist Hospital - Houston
Georgia
- Emory University Hospital - Atlanta
Kansas
- Kansas University Medical Center - Kansas City
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2015-01-21 |
| Est. Completion | 2021-09-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02310100
The ClinicalTrials.gov registry entry for NCT02310100 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 852-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (79% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which TactiCath Quartz treatment is the first listed.
NCT02310100 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT02310100 about?
NCT02310100 is a clinical study titled "TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study". A prospective, multicenter, interventional study to collect confirmatory evidence on the safety and effectiveness of the TactiCath® percutaneous ablation catheter in the post approval setting for the treatment of symptomatic paroxysmal atrial fibrillation using contact force assisted irrigated radio...
What is the current status of trial NCT02310100?
This trial is currently completed. It is a NA study. The enrollment target is 178 participants. The study started on 2015-01-21. Estimated completion is 2021-09-17.
What conditions does trial NCT02310100 study?
This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation.
What interventions are being tested in trial NCT02310100?
The interventions under investigation include: TactiCath Quartz treatment (DEVICE).
Who is sponsoring clinical trial NCT02310100?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02310100 being conducted?
This trial has 20 study locations across California, Georgia, Kansas, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
RECRUITING · NA
-
POLARx Post Approval Study (POLARx PAS)
RECRUITING · NA
-
Treatment of PAF With the Synaptic System
ACTIVE NOT RECRUITING · NA
-
Meditation and Education That is Nurse Delivered for Symptom Management in Paroxysmal Atrial Fibrillation (PAF)
ACTIVE NOT RECRUITING · NA
-
Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.